Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 51

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Epilepsy

Not yet recruiting

Efficacy of fluoxetine added to standard anti‑seizure therapy in children aged 8 years and older with drug‑resistant complex and rare epilepsy

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Fluoxetine
  • Sponsor:Centre Hospitalier Regional De Marseille

Gaucher's disease type III

Not yet recruiting

Efficacy and safety of oral venglustat versus intravenous imiglucerase in children aged 2‑11 years with Gaucher disease type 3

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Imiglucerase
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Intracranial aneurysm

Not yet recruiting

Comparing two heparin sodium doses on silent brain lesions in patients undergoing embolization of unruptured intracranial aneurysm with drug combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Neurodegenerative disorder

Not yet recruiting

Study of dimethyl fumarate safety and efficacy in patients with Neurodegeneration with Brain Iron Accumulation (NBIA), including PKAN and MPAN

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dimethyl Fumarate
  • Sponsor:Instytut Psychiatrii I Neurologii

Cerebrovascular accident

Not yet recruiting

Effect of baclofen, gabapentin and oxazepam on brain plasticity and motor learning in subacute stroke patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Baclofen
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Parkinson's disease

Not yet recruiting

Study of VQ-101 to Slow Progression in Adults with GBA1‑Associated Parkinson’s Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Vanqua Bio Inc.

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Spinal muscular atrophy

Not yet recruiting

Safety and Efficacy of Intrathecal BIIB115 in Infants with Spinal Muscular Atrophy Previously Treated with Onasemnogene Abeparvovec

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:BIIB115
  • Sponsor:Biogen Idec Research Limited

Subarachnoid haemorrhage+4

Not yet recruiting

Prehospital Sedation with Esketamine versus Propofol in Patients with Severe Acute Brain Injury

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Propofol
  • Sponsor:Region Hovedstaden

Fabry's disease

Not yet recruiting

Efficacy and Safety of Lucerastat in Treatment‑Naïve Adult Male Patients with Fabry Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Lucerastat
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Ischaemic stroke

Not yet recruiting

Effectiveness of Tenecteplase in Acute Ischemic Stroke Patients Treated 4.5–24 Hours After Onset Before Transfer for Thrombectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Fondation A De Rothschild

Partial seizures

Not yet recruiting

Safety and tolerability of OV329 as add‑on therapy in adults with drug‑resistant focal epilepsy

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.